Gilead Sciences Files 10-Q for Q2 2024
Ticker: GILD · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Gilead 10-Q filed. Q2 & H1 2024 results out.
AI Summary
Gilead Sciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the year. Key financial data and operational details are disclosed in this filing, which covers the period from January 1, 2024, to June 30, 2024.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational updates for Gilead Sciences, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial and operational updates.
Key Numbers
- 2024-06-30 — Period End Date (Quarterly reporting period)
- 2024-01-01 — Period Start Date (Quarterly reporting period)
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Filer
- 20240630 (date) — Period of Report
- 20240808 (date) — Filing Date
- 0000882095 (company) — Central Index Key
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period of report ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 8, 2024.
What is the Central Index Key for Gilead Sciences, Inc.?
The Central Index Key for Gilead Sciences, Inc. is 0000882095.
What is the Standard Industrial Classification for Gilead Sciences, Inc.?
The SIC code for Gilead Sciences, Inc. is 2836, which corresponds to Biological Products (no diagnostic substances).
What is the fiscal year end for Gilead Sciences, Inc.?
Gilead Sciences, Inc.'s fiscal year ends on December 31.
From the Filing
0000882095-24-000022.txt : 20240808 0000882095-24-000022.hdr.sgml : 20240808 20240808171759 ACCESSION NUMBER: 0000882095-24-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 241189668 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 10-Q 1 gild-20240630.htm FORM 10-Q gild-20240630 0000882095 12/31 2024 Q2 false 365 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:EUR xbrli:pure gild:designee gild:agreement gild:patent gild:claim gild:lawsuit gild:plaintiff 0000882095 2024-01-01 2024-06-30 0000882095 2024-07-31 0000882095 2024-06-30 0000882095 2023-12-31 0000882095 us-gaap:ProductMember 2024-04-01 2024-06-30 0000882095 us-gaap:ProductMember 2023-04-01 2023-06-30 0000882095 us-gaap:ProductMember 2024-01-01 2024-06-30 0000882095 us-gaap:ProductMember 2023-01-01 2023-06-30 0000882095 gild:RoyaltyContractAndOtherMember 2024-04-01 2024-06-30 0000882095 gild:RoyaltyContractAndOtherMember 2023-04-01 2023-06-30 0000882095 gild:RoyaltyContractAndOtherMember 2024-01-01 2024-06-30 0000882095 gild:RoyaltyContractAndOtherMember 2023-01-01 2023-06-30 0000882095 2024-04-01 2024-06-30 0000882095 2023-04-01 2023-06-30 0000882095 2023-01-01 2023-06-30 0000882095 us-gaap:CommonStockMember 2024-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000882095 us-gaap:RetainedEarningsMember 2024-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2024-03-31 0000882095 2024-03-31 0000882095 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000882095 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000882095 us-gaap:CommonStockMember 2024-06-30 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000882095 us-gaap:RetainedEarningsMember 2024-06-30 0000882095 us-gaap:NoncontrollingInterestMember 2024-06-30 0000882095 us-gaap:CommonStockMember 2023-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2023-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0000882095 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000882095 us-gaap:CommonStockMember 2023-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000882095 us-gaap:RetainedEarningsMember 2023-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-03-31 0000882095 2023-03-31 0000882095 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000882095 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000882095 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 00008820